180 related articles for article (PubMed ID: 22039528)
1. Picomolar dichotomous activity of gnidimacrin against HIV-1.
Huang L; Ho P; Yu J; Zhu L; Lee KH; Chen CH
PLoS One; 2011; 6(10):e26677. PubMed ID: 22039528
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Structure-Activity Relationship Correlations of Gnidimacrin Derivatives as Potent HIV-1 Inhibitors and HIV Latency Reversing Agents.
Liu Q; Cheng YY; Li W; Huang L; Asada Y; Hsieh MT; Morris-Natschke SL; Chen CH; Koike K; Lee KH
J Med Chem; 2019 Aug; 62(15):6958-6971. PubMed ID: 31343875
[TBL] [Abstract][Full Text] [Related]
3. Gnidimacrin, a Potent Anti-HIV Diterpene, Can Eliminate Latent HIV-1 Ex Vivo by Activation of Protein Kinase C β.
Lai W; Huang L; Zhu L; Ferrari G; Chan C; Li W; Lee KH; Chen CH
J Med Chem; 2015 Nov; 58(21):8638-46. PubMed ID: 26509731
[TBL] [Abstract][Full Text] [Related]
4. Daphneodorins A-C, Anti-HIV Gnidimacrin Related Macrocyclic Daphnane Orthoesters from
Otsuki K; Li W; Asada Y; Chen CH; Lee KH; Koike K
Org Lett; 2020 Jan; 22(1):11-15. PubMed ID: 31680527
[TBL] [Abstract][Full Text] [Related]
5. Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR.
Abreu CM; Price SL; Shirk EN; Cunha RD; Pianowski LF; Clements JE; Tanuri A; Gama L
PLoS One; 2014; 9(5):e97257. PubMed ID: 24827152
[TBL] [Abstract][Full Text] [Related]
6. Elimination of HIV-1 Latently Infected Cells by Gnidimacrin and a Selective HDAC Inhibitor.
Huang L; Lai WH; Zhu L; Li W; Wei L; Lee KH; Xie L; Chen CH
ACS Med Chem Lett; 2018 Mar; 9(3):268-273. PubMed ID: 29541372
[TBL] [Abstract][Full Text] [Related]
7. Novel phorbol esters exert dichotomous effects on inhibition of HIV-1 infection and activation of latent HIV-1 expression.
Zhong Y; Matsuya Y; Nemoto H; Mori M; Saito H; Yamamoto N
Antivir Chem Chemother; 2005; 16(5):303-13. PubMed ID: 16245646
[TBL] [Abstract][Full Text] [Related]
8. SJ23B, a jatrophane diterpene activates classical PKCs and displays strong activity against HIV in vitro.
Bedoya LM; Márquez N; Martínez N; Gutiérrez-Eisman S; Alvarez A; Calzado MA; Rojas JM; Appendino G; Muñoz E; Alcamí J
Biochem Pharmacol; 2009 Mar; 77(6):965-78. PubMed ID: 19100719
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of daphnane-type diterpene gnidimacrin isolated from Stellera chamaejasme L.
Yoshida M; Feng W; Saijo N; Ikekawa T
Int J Cancer; 1996 Apr; 66(2):268-73. PubMed ID: 8603823
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV-1 replication in human primary cells by a dolabellane diterpene isolated from the marine algae Dictyota pfaffii.
Cirne-Santos CC; Teixeira VL; Castello-Branco LR; Frugulhetti IC; Bou-Habib DC
Planta Med; 2006 Mar; 72(4):295-9. PubMed ID: 16557468
[TBL] [Abstract][Full Text] [Related]
12. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
[TBL] [Abstract][Full Text] [Related]
13. Novel reporter T-cell line highly susceptible to both CCR5- and CXCR4-using human immunodeficiency virus type 1 and its application to drug susceptibility tests.
Miyake H; Iizawa Y; Baba M
J Clin Microbiol; 2003 Jun; 41(6):2515-21. PubMed ID: 12791875
[TBL] [Abstract][Full Text] [Related]
14. Antitumor action of the PKC activator gnidimacrin through cdk2 inhibition.
Yoshida M; Feng W; Nishio K; Takahashi M; Heike Y; Saijo N; Wakasugi H; Ikekawa T
Int J Cancer; 2001 Nov; 94(3):348-52. PubMed ID: 11745413
[TBL] [Abstract][Full Text] [Related]
15. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
Symons J; van Lelyveld SF; Hoepelman AI; van Ham PM; de Jong D; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2011 Apr; 66(4):890-5. PubMed ID: 21393136
[TBL] [Abstract][Full Text] [Related]
16. Involvement of PKC betaII in anti-proliferating action of a new antitumor compound gnidimacrin.
Yoshida M; Heike Y; Ohno S; Ikekawa T; Wakasugi H
Int J Cancer; 2003 Jul; 105(5):601-6. PubMed ID: 12740906
[TBL] [Abstract][Full Text] [Related]
17. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
Takashima K; Miyake H; Kanzaki N; Tagawa Y; Wang X; Sugihara Y; Iizawa Y; Baba M
Antimicrob Agents Chemother; 2005 Aug; 49(8):3474-82. PubMed ID: 16048963
[TBL] [Abstract][Full Text] [Related]
18. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
[TBL] [Abstract][Full Text] [Related]
19. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
[TBL] [Abstract][Full Text] [Related]
20. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy.
Delobel P; Sandres-Sauné K; Cazabat M; Pasquier C; Marchou B; Massip P; Izopet J
J Acquir Immune Defic Syndr; 2005 Apr; 38(4):382-92. PubMed ID: 15764954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
